drug affinity complex comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
microtubule-organizing center (MTOC) A region near the center of a eukaryotic cell typically consisting of two centrioles oriented at right angles to each other and surrounded by a complex of associated proteins, which functions as the site of initiation for the assembly of microtubules.
The united armies of the Holy League expelled the Ottoman troops from Central Europe between 1684 and 1699, and the Principality of Transylvania was integrated into the Habsburg monarchy. The Habsburgs supported the Catholic clergy and persuaded the Orthodox Romanian prelates to accept the union with the Roman Catholic Church in 1699. In the 18th century, Moldavia and Wallachia maintained their internal autonomy, but in 1711 and 1716, respectively, the period of the Phanariots began, with rulers appointed directly by the Porte from among the noble families of Greek origin in Constantinople. With the signing of the Ausgleich in 1867, Transylvania quickly lost its remaining political autonomy, being politically and administratively incorporated into the Kingdom of Hungary. The Church Union strengthened the Romanian intellectuals' devotion to their Roman heritage. The Orthodox Church was restored in Transylvania only after Orthodox monks stirred up revolts in 1744 and 1759. The organisation of the Transylvanian Military Frontier caused further disturbances, especially among the Székelys in 1764. Princes Dimitrie Cantemir of Moldavia and Constantin Brâncoveanu of Wallachia concluded alliances with the Habsburg Monarchy and Russia against the Ottomans, but they were dethroned in 1711 and 1714, respectively. The sultans lost confidence in the native princes and appointed Orthodox merchants from the Phanar district of Istanbul to rule Moldavia and Wallachia. The Phanariot princes pursued oppressive fiscal policies and dissolved the army.
However, up to 10% of cases are due to a new mutation. Expansion of CAG repeats (known as a trinucleotide repeat expansion) in the gene coding for the huntingtin protein results in an abnormal mutant protein (mHTT), which gradually damages brain cells through a number of possible mechanisms. The mutant protein is dominant, so having one parent who is a carrier of the trait is sufficient to trigger the disease in their children. Diagnosis is by genetic testing, which can be carried out at any time, regardless of whether or not symptoms are present. This fact raises several ethical debates: the age at which an individual is considered mature enough to choose testing; whether parents have the right to have their children tested; and managing confidentiality and disclosure of test results. No cure for HD is known, and full-time care is required in the later stages. Treatments can relieve some symptoms and possibly improve quality of life. The best evidence for treatment of the movement problems is with tetrabenazine. HD affects about 4 to 15 in 100,000 people of European descent. It is rare among the Finnish and the Japanese, while the incidence in Africa is unknown. The disease affects males and females equally. Complications such as pneumonia, heart disease, and physical injury from falls reduce life expectancy; fatal aspiration pneumonia is commonly cited as the ultimate cause of death for those with the condition. Suicide is the cause of death in about 9% of cases. Death typically occurs 15–20 years from when the disease was first detected.
Sources: en.wikipedia.org
== Transcriptional regulation == SREBPs have been found to play a role with the nutritional or hormonal effects on the lipogenic gene expression. Overexpression of SREBP-1a or SREBP-1c in mouse liver cells results in the build-up of hepatic triglycerides and higher expression levels of lipogenic genes. Lipogenic gene expression in the liver via glucose and insulin is moderated by SREBP-1. The effect of glucose and insulin on the transcriptional factor can occur through various pathways; there is evidence suggesting that insulin promotes SREBP-1 mRNA expression in adipocytes and hepatocytes. It has also been suggested that the hormone increases transcriptional activation by SREBP-1 through MAP-kinase-dependent phosphorylation regardless of changes in the mRNA levels. Along with insulin glucose also have been shown to promote SREBP-1 activity and mRNA expression.
Through the centuries, a variety of techniques for processing tea, and a number of different forms of tea, were developed. During the Han and Six Dynasties, tea was steamed and pounded, shaped into cake form, slowly dried over low fire, and suspended to air dry. Chunks of tea were then boiled to drink, flavoured with orange peels, jujube, mint, ginger or scallion. Tea was similarly prepared in cake form during the Tang dynasty, but Lu Yu disparaged the use of various condiments to flavour the tea apart from salt. By the Song dynasty, loose-leaf tea was developed and became common. During the Yuan and Ming dynasties, unoxidized tea leaves were first stirred in a hot dry pan, then rolled and air-dried, a process that stops the oxidation process that would have turned the leaves dark, thereby allowing tea to remain green. In the 15th century, oolong tea, in which the leaves are allowed to partially oxidize before being heated in the pan, was developed. Western tastes, however, favoured the fully oxidized black tea, and the leaves were allowed to oxidize further. Yellow tea was an accidental discovery in the production of green tea during the Ming dynasty, when apparently careless practices allowed the leaves to turn yellow, which yielded a different flavour.
People who inherit one copy of the HbE gene and one copy of the normal β-globin gene (HbA) are said to "carry the HbE trait", and are asymptomatic, as are most people who inherit two copies of HbE. However, inheritance of one HbE copy and one copy of HBB with a different mutation, such as one that causes β-thalassemia or sickle cell anemia, leads to a thalassemia ranging from mild to severe depending on the nature of the second mutation. Minnich was the first person to describe hemoglobin E/β-thalassemia, in 1951. Her work led to further research into this disease, which is estimated to affect a million people worldwide. HbE is considered to be one of the most common genetic mutations, with carrier rates approaching 60% in some parts of Southeast Asia, and testing for HbE is now part of routine neonatal screening and genetic counseling. Pica In 1965, while in Turkey setting up a hematology laboratory at the University of Ankara, Minnich noticed a form of pica involving clay eating. When she followed up this research upon her return to Washington University, she found a similar clay eating practice in parts of the United States. Pica had been known to be associated with iron deficiency but the cause/effect relationship was unclear; Minnich found that that clay actually made iron deficiency worse by acting as a chelating agent, binding iron in the bloodstream and removing it from the body.
Chloramphenicol binds to residues A2451 and A2452 in the 23S rRNA of the ribosome and inhibits peptide bond formation. Pleuromutilins also bind to the peptidyl transferase center. Macrolide antibiotics are thought to inhibit peptidyl transferase, in addition to inhibiting ribosomal translocation.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.